Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses
Rinke Bos, Lucy Rutten, Joan E M van der Lubbe, Mark J G Bakkers, Gijs Hardenberg, Frank Wegmann, David Zuijdgeest, Adriaan H de Wilde, Annemart Koornneef, Annemiek Verwilligen, Danielle van Manen, Ted Kwaks, Ronald Vogels, Tim J Dalebout, Sebenzile K Myeni, Marjolein Kikkert, Eric J Snijder, Zhenfeng Li, Dan H Barouch, Jort Vellinga, Johannes P M Langedijk, Roland C Zahn, Jerome Custers, Hanneke Schuitemaker, Rinke Bos, Lucy Rutten, Joan E M van der Lubbe, Mark J G Bakkers, Gijs Hardenberg, Frank Wegmann, David Zuijdgeest, Adriaan H de Wilde, Annemart Koornneef, Annemiek Verwilligen, Danielle van Manen, Ted Kwaks, Ronald Vogels, Tim J Dalebout, Sebenzile K Myeni, Marjolein Kikkert, Eric J Snijder, Zhenfeng Li, Dan H Barouch, Jort Vellinga, Johannes P M Langedijk, Roland C Zahn, Jerome Custers, Hanneke Schuitemaker
Abstract
Development of effective preventative interventions against SARS-CoV-2, the etiologic agent of COVID-19 is urgently needed. The viral surface spike (S) protein of SARS-CoV-2 is a key target for prophylactic measures as it is critical for the viral replication cycle and the primary target of neutralizing antibodies. We evaluated design elements previously shown for other coronavirus S protein-based vaccines to be successful, e.g., prefusion-stabilizing substitutions and heterologous signal peptides, for selection of a S-based SARS-CoV-2 vaccine candidate. In vitro characterization demonstrated that the introduction of stabilizing substitutions (i.e., furin cleavage site mutations and two consecutive prolines in the hinge region of S2) increased the ratio of neutralizing versus non-neutralizing antibody binding, suggestive for a prefusion conformation of the S protein. Furthermore, the wild-type signal peptide was best suited for the correct cleavage needed for a natively folded protein. These observations translated into superior immunogenicity in mice where the Ad26 vector encoding for a membrane-bound stabilized S protein with a wild-type signal peptide elicited potent neutralizing humoral immunity and cellular immunity that was polarized towards Th1 IFN-γ. This optimized Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in a phase I clinical trial (ClinicalTrials.gov Identifier: NCT04436276).
Keywords: SARS-CoV-2; Vaccines; Viral infection.
Conflict of interest statement
Competing interestsThe authors declare no competing financial interests. R.B., L.R., M.J.G.B., F.W., D.Z., and J.P.L. are co-inventors on related vaccine patents. R.B., L.R., J.E.M.vd.L., M.J.G.B., G.H., F.W., D.Z., A.H.d.W., A.K., A.V., D.v.M., T.K., R.V., J.V., J.P.M.L., R.C.Z, J.C., and H.S. are employees of Janssen Vaccines & Prevention BV. R.B., L.R., F.W., D.Z., D.v.M., T.K., R.V., J.V., J.P.M.L., R.C.Z, J.C., and H.S. hold stock of Johnson & Johnson.
© The Author(s) 2020.
Figures
References
- Coronaviridae Study Group of the International Committee on Taxonomy of, V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020;5:536–544. doi: 10.1038/s41564-020-0695-z.
- Sternberg A, Naujokat C. Structural features of coronavirus SARS-CoV-2 spike protein: targets for vaccination. Life Sci. 2020;257:118056. doi: 10.1016/j.lfs.2020.118056.
- Krarup A, et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 2015;6:8143. doi: 10.1038/ncomms9143.
- Rutten L, et al. A universal approach to optimize the folding and stability of prefusion-closed HIV-1 envelope trimers. Cell Rep. 2018;23:584–595. doi: 10.1016/j.celrep.2018.03.061.
- Sanders RW, et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 2002;76:8875–8889. doi: 10.1128/JVI.76.17.8875-8889.2002.
- Rutten L, et al. Structure-based design of prefusion-stabilized filovirus glycoprotein trimers. Cell Rep. 2020;30:4540–4550. doi: 10.1016/j.celrep.2020.03.025.
- Battles MB, et al. Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein. Nat. Commun. 2017;8:1528. doi: 10.1038/s41467-017-01708-9.
- Hastie KM, et al. Structural basis for antibody-mediated neutralization of Lassa virus. Science. 2017;356:923–928. doi: 10.1126/science.aam7260.
- Kirchdoerfer RN, et al. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci. Rep. 2018;8:15701. doi: 10.1038/s41598-018-34171-7.
- Pallesen J, et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl Acad. Sci. USA. 2017;114:E7348–E7357. doi: 10.1073/pnas.1707304114.
- Walls AC, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281–292. doi: 10.1016/j.cell.2020.02.058.
- Wrapp D, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. doi: 10.1126/science.abb2507.
- Alharbi NK, et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine. 2017;35:3780–3788. doi: 10.1016/j.vaccine.2017.05.032.
- Martin JE, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008;26:6338–6343. doi: 10.1016/j.vaccine.2008.09.026.
- Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature10.1038/s41586-020-2622-0 (2020).
- Smith TRF, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 2020;11:2601. doi: 10.1038/s41467-020-16505-0.
- van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature10.1038/s41586-020-2608-y (2020).
- Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science10.1126/science.abc6284 (2020).
- Honda-Okubo Y, et al. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J. Virol. 2015;89:2995–3007. doi: 10.1128/JVI.02980-14.
- Iwata-Yoshikawa N, et al. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J. Virol. 2014;88:8597–8614. doi: 10.1128/JVI.00983-14.
- Tseng CT, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE. 2012;7:e35421. doi: 10.1371/journal.pone.0035421.
- Anywaine Z, et al. Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania. J. Infect. Dis. 2019;220:46–56. doi: 10.1093/infdis/jiz070.
- Baden LR, et al. Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial. Ann. Intern. Med. 2016;164:313–322. doi: 10.7326/M15-0880.
- Baden LR, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001) J. Infect. Dis. 2013;207:240–247. doi: 10.1093/infdis/jis670.
- Mutua G, et al. Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya. J. Infect. Dis. 2019;220:57–67. doi: 10.1093/infdis/jiz071.
- Shukarev, G., Callendret, B., Luhn, K., Douoguih, M. & consortium, E. A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks. Hum. Vaccin Immunother. 13, 266–270 (2017).
- Winslow RL, et al. Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored Ebola vaccines at 1 year. JAMA. 2017;317:1075–1077. doi: 10.1001/jama.2016.20644.
- Barouch DH, et al. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001) J. Infect. Dis. 2013;207:248–256. doi: 10.1093/infdis/jis671.
- Barouch DH, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) Lancet. 2018;392:232–243. doi: 10.1016/S0140-6736(18)31364-3.
- Liu J, et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 2008;82:4844–4852. doi: 10.1128/JVI.02616-07.
- Milligan ID, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA. 2016;315:1610–1623. doi: 10.1001/jama.2016.4218.
- Radosevic K, et al. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin. Vaccin. Immunol. 2010;17:1687–1694. doi: 10.1128/CVI.00311-10.
- van der Fits L, et al. Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice. npj Vaccines. 2020;5:49. doi: 10.1038/s41541-020-0200-y.
- Pinto D, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583:290–295. doi: 10.1038/s41586-020-2349-y.
- Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv. Virus Res. 2019;105:93–116. doi: 10.1016/bs.aivir.2019.08.002.
- Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature10.1038/s41586-020-2607-z (2020).
- Lindblad EB. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 2004;82:497–505. doi: 10.1111/j.0818-9641.2004.01286.x.
- Chandrashekar, A. et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science10.1126/science.abc4776 (2020).
- Gilbert, S. C., Hill, A. V. S. & Moris, S. J. Compositions and methods for inducing an immune response. patent WO 2018/215766 Al (2017).
- Liu P, et al. Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney Int. 2018;94:114–125. doi: 10.1016/j.kint.2018.01.029.
- van den Brink EN, et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J. Virol. 2005;79:1635–1644. doi: 10.1128/JVI.79.3.1635-1644.2005.
- Abbink P, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 2007;81:4654–4663. doi: 10.1128/JVI.02696-06.
- Wunderlich, K. et al. Potent and short promoter for expression of heterologous genes. patent WO/2018/146205 (2018).
- Zahn R, et al. Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS ONE. 2012;7:e44115. doi: 10.1371/journal.pone.0044115.
- Maizel JV, Jr., White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology. 1968;36:115–125. doi: 10.1016/0042-6822(68)90121-9.
- Wang F, et al. Using QPCR to assign infectious potencies to adenovirus based vaccines and vectors for gene therapy: toward a universal method for the facile quantitation of virus and vector potency. Vaccine. 2005;23:4500–4508. doi: 10.1016/j.vaccine.2005.04.023.
- Algaissi A, Hashem AM. Evaluation of MERS-CoV neutralizing antibodies in sera using live virus microneutralization assay. Methods Mol. Biol. 2020;2099:107–116. doi: 10.1007/978-1-0716-0211-9_9.
- Hierholzer, J. C. & Killington, R. A. in Virology Methods Manual 1st edn. 25–46 (Academic Press, 1996).
- Millet, J. K. & Whittaker, G. R. Murine Leukemia Virus (MLV)-based coronavirus Spike-pseudotyped particle production and infection. Bio Protoc. 10.21769/BioProtoc.2035 (2016).
Source: PubMed